Impact Investing in Cardiovascular Disease

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Getting Treatments to Patients

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Diversified Portfolio Across Technologies

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

OUR PORTFOLIO

View All

PRESS

Jun 23, 2026

CroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study

Jun 9, 2026

Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

Jun 7, 2026

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a firstin- class GIPR antagonist

May 27, 2026

Cardiosense Receives FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure

View All